Özet:

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, from the family of coronavirus in the People's Republic of China's state of Wuhan, has shown a very rapid spread in a very short time and has shown its effects throughout the world. The World Health Organization (WHO) declared the disease as a pandemic on 11 March 2020. Convelesan plasma (KP) treatment is a passive antibodies therapy that has been shown to be effective, used in epidemic periods of history. The mechanisms of effect of convelesan plasma can include neutralizing the virus by directly linking, initiating the virus elimination by means of complementary activation, antibodies-dependent cellular cytotoxicity and/or fagositosis. The neutralizing antibodies are very important in these mechanisms of action. Preventing viral replication by inactivating the virus is an important point of healing. Therefore, the KP is also important for the measurement of the neutralized antibodies. It has been shown in vitro that non-neutralized antibodies do not stop viral replication, and it has been suggested that these antibodies can be used in profylaxis, have a supporting effect in healing. In studies with COVID-19 disease, KP has also been shown to be effective. In our country and in America, the criteria for the application of this method of treatment, which has recently been indicated for treatment, have been determined by both countries. The results of convelesan plasma treatment transmitted from appropriate donors to patients that may be beneficial are expected with curiosity.